GlycoSeLect
OverviewSuggest Edit
GlycoSeLect is a company that specializes in the development and production of Recombinant Prokaryotic Lectins (RPLs). They enable detection, analysis, separation, and purification of intact glycosylated biomolecules.
| Type | Private | |
| Founded | 2013 | |
| HQ | Dublin 9, IE | Map |
| Website | glycoselect.com |
Latest Updates
| Employees (est.) (Apr 2022) | 10 | |
| Cybersecurity rating | A | More |
GlycoSeLect Financials and Metrics
Summary Metrics
Founding Date | 2013 |
GlycoSeLect total Funding | $528.8 k |
GlycoSeLect latest funding size | $528.82 k |
Time since last funding | 5 years ago |
GlycoSeLect investors | Enterprise Ireland, KBI Biopharma |
GlycoSeLect's latest funding round in October 2017 was reported to be $528.8 k. In total, GlycoSeLect has raised $528.8 k
GlycoSeLect Cybersecurity Score
GlycoSeLect Online and Social Media Presence
283 Twitter followers
GlycoSeLect has 283 Twitter Followers. The number of followers has increased 1.3% month over month and increased 5.9% quarter over quarter
GlycoSeLect's Trends
Twitter Engagement Stats for @glycoselect
169
Tweets
657
Following
283
Followers
13
Tweets last 30 days
1
Avg. likes per Tweet
76.9%
Tweets with engagement
GlycoSeLect Blogs
April 05, 2022
Simplifying Glycoanalysis with Recombinant Prokaryotic Lectins
Glycosylation is a post-translational modification (PTM) that can influence protein structure and function. It is therefore a Critical Quality Attribute (CQA) for biotherapeutic manufacturing, where it must be closely monitored to assure product safety and efficacy. Limitations of current glycoanaly…
December 20, 2021
Streamline Purification of Glycosylated Proteins with Recombinant Prokaryotic Lectins
Glycosylation affects the safety and efficacy of biologic drugs, making it a Critical Quality Attribute (CQA) for biotherapeutic manufacturing. Recombinant prokaryotic lectins (RPLs) provide several advantages for purifying glycosylated biotherapeutics and are applicable to both glycoanalysis and do…
December 01, 2021
GlycoSeLect signs distribution agreement with MJS BioLynx Inc.
November 2021 GlycoSeLect is delighted to announce that it has signed an exclusive distribution agreement for its innovative RPL glycan specific technology in the Canadian market with MJS BioLynx Inc. MJS BioLynx Inc. is a Canadian life sciences distribution company with over 40 years of distributio…
September 27, 2021
GlycoSeLect enters strategic agreement with DBA Italia
Dublin-Milan, September 2021 GlycoSeLect is pleased to announce that we have entered into a strategic agreement with DBA Italia, Milan, Italy. Effective from October 1st, 2021, DBA Italia s.r.l. is appointed as GlycoSeLect’s distributor for Italy for our innovative recombinant lectin products, devot…
August 27, 2021
New webinar on glycoanalytics features GlycoSeLect
Last month, BioPharm International hosted a webinar on Novel High-Throughput Glycoanalytics for Biopharmaceuticals, sponsored by Sartorius, and aimed at those interested in learning more about the detection of glycans in biopharmaceutical samples. During the presentation, Victoria Smith and Lewis Wh…
August 23, 2021
Targeting key glycoproteins: Glucose oxidase
Using GlycoSeLect RPL products to enable the isolation and identification of key protein glucose oxidase in a variety of applications. By Simarjot Kaur, Scientist at GlycoSeLect. GlycoSeLect specializes in the manufacture and delivery of Recombinant Prokaryotic Lectins (RPLs), highly specific glycan…
GlycoSeLect Frequently Asked Questions
When was GlycoSeLect founded?
GlycoSeLect was founded in 2013.
How many employees does GlycoSeLect have?
GlycoSeLect has 10 employees.
Who are GlycoSeLect competitors?
Competitors of GlycoSeLect include Aurobindo Pharma, Unither Pharmaceuticals and Patheon.
Where are GlycoSeLect offices?
GlycoSeLect has an office in Dublin 9.
How many offices does GlycoSeLect have?
GlycoSeLect has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies